CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITE...( ORLANDO Fla. March 29 /- Results ...),Health

ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Results from a new sub- analysis of the JUPITER study show that patients with low to normal cholesterol levels and elevated high sensitivity C-reactive protein (hsCRP) who attained a dual treatment target of LDL-C <70mg/dL and hsCRP <2mg/L with CRESTOR(R) (rosuvastatin calcium) 20mg achieved a greater reduction in cardiovascular events compared to placebo than those who did not (65% vs 36%; p=0.033). These new data were presented at the 58th Annual American College of Cardiology Scientific Sessions (ACC) in Orlando, Florida, and published simultaneously in The Lancet.

This analysis was conducted in approximately 15,500 patients, or 87% of the entire JUPITER cohort, representing patients who had LDL-C and hsCRP values assessed at baseline and one year.

Additional results from this analysis showed:

-- Patients who achieved an LDL-C <70 mg/dL experienced a 55% reduction in cardiovascular events compared to placebo

-- Patients who achieved a dual treatment target of LDL-C<70 mg/dL and hsCRP <1 mg/L achieved a 79% reduction in CV events compared to placebo

"JUPITER demonstrated the effect of rosuvastatin on cardiovascular morbidity and mortality," said Alex Gold, MD, Executive Director, Clinical Development, AstraZeneca US. "In this analysis, patients treated with rosuvastatin who achieved low levels of LDL-C and hsCRP had a greater reduction in cardiovascular events."

Rosuvastatin 20mg was well tolerated in nearly 9,000 patients during the course of the JUPITER study.

ABOUT JUPITER:

Results from the primary analysis of JUPITER (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin), originally presented in November 2008 at the American Heart Association's Annual Scientific Sessions, and published by the
'/>"/>